Loading...

Hyunseok Kang, MD

TitleAssociate Professor
InstitutionUniversity of California San Francisco
DepartmentMedicine
Address1600 Divisadero
San Francisco CA 94115
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Yonsei University, Seoul, KoreaM.D.02/2002Medicine
    Yonsei University, Seoul, KoreaM.P.H.08/2007Epidemiology & Statistics
    St.Luke's-Roosevelt Hospital/Columbia University, New York, NYResidency06/2010Internal Medicine
    Emory University, Atlanta, GAFellowship06/2013Hematology&Oncology
    Collapse Awards and Honors
    Ministry of Health and Welfare of Korea2005  - 2005Excellence in Service Award
    AACR/ASCO2012  - 2012Travel Award for Methods in Clinical Research Workshop
    American College of Physicians2015Elected to a fellow (FACP)

    Collapse Overview 
    Collapse Overview
    Dr.Hyunseok "Hyu" Kang is a medical oncologist and a clinician scientist focusing on head and neck cancers including squamous cell carcinomas of head and neck (SCCHN), salivary gland cancers, thyroid cancers and other rare cancers of head and neck. Dr.Kang joined UCSF from the Johns Hopkins University School of Medicine in Baltimore, MD where he was an Assistant Professor of Oncology, Otolaryngology - Head and Neck Surgery.

    Dr.Kang completed his medical degree and public health degree at Yonsei University in Seoul, South Korea, then came to the US and had residency training at St.Luke's Roosevelt Hospital Center/Columbia University in New York City. He completed hematology and medical oncology fellowship at Emory University in Atlanta, GA.

    Dr.Kang's research focus is development of clinical trials with novel therapeutic agents for patients with head and neck cancers. He has conducted/participated a number of clinical trials with immune checkpoint inhibitors and targeted therapy agents.


    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Park JC, Gourin CG, Kiess AP, Mehra R, Forastiere AA, Kang H. Pattern of planned systemic therapy usage in newly diagnosed, nonmetastatic squamous cell carcinoma of the head and neck in a commercially insured population in the United States. Head Neck. 2018 Nov 13. PMID: 30421818.
      View in: PubMed
    2. Kang H, Pettinga D, Schubert AD, Ladenson PW, Ball DW, Chung JH, Schrock AB, Madison R, Frampton GM, Stephens PJ, Ross JS, Miller VA, Ali SM. Genomic Profiling of Parathyroid Carcinoma Reveals Genomic Alterations Suggesting Benefit from Therapy. Oncologist. 2018 Oct 29. PMID: 30373905.
      View in: PubMed
    3. Kwatra SG, Ständer S, Kang H. PD-1 Blockade-Induced Pruritus Treated with a Mu-Opioid Receptor Antagonist. N Engl J Med. 2018 Oct 18; 379(16):1578-1579. PMID: 30332571.
      View in: PubMed
    4. Karantanos T, Rooper L, Kang Y, Lin CT, Wenga P, Sagorsky S, Lauring J, Kang H. Clinical Benefit to an Aurora A Kinase Inhibitor in a Patient with Metastatic Integrase Interactor 1-Deficient Carcinoma. Oncologist. 2018 Oct 08. PMID: 30297384.
      View in: PubMed
    5. Ho WJ, Yarchoan M, Hopkins A, Mehra R, Grossman S, Kang H. Association between pretreatment lymphocyte count and response to PD1 inhibitors in head and neck squamous cell carcinomas. J Immunother Cancer. 2018 Aug 31; 6(1):84. PMID: 30170629.
      View in: PubMed
    6. Jung K, Park JC, Kang H, Brandes J. Androgen deprivation therapy is associated with decreased second primary lung cancer risk in the US veterans with prostate cancer. Epidemiol Health. 2018 Aug 11. PMID: 30121970.
      View in: PubMed
    7. Rooper LM, Karantanos T, Ning Y, Bishop JA, Gordon SW, Kang H. Salivary Secretory Carcinoma With a Novel ETV6-MET Fusion: Expanding the Molecular Spectrum of a Recently Described Entity. Am J Surg Pathol. 2018 Aug; 42(8):1121-1126. PMID: 29683815.
      View in: PubMed
    8. Mehra R, Seiwert TY, Gupta S, Weiss J, Gluck I, Eder JP, Burtness B, Tahara M, Keam B, Kang H, Muro K, Geva R, Chung HC, Lin CC, Aurora-Garg D, Ray A, Pathiraja K, Cheng J, Chow LQM, Haddad R. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. Br J Cancer. 2018 Jul; 119(2):153-159. PMID: 29955135.
      View in: PubMed
    9. Kang H, Antonarakis ES, Luo J, Zheng Q, Rooper L, De Marzo AM, Westra WH, Lotan TL. Detection of AR-V7 transcript with RNA in situ hybridization in human salivary duct cancer. Oral Oncol. 2018 Sep; 84:134-136. PMID: 30122219.
      View in: PubMed
    10. Ho WJ, Rooper L, Sagorsky S, Kang H. A robust response to combination immune checkpoint inhibitor therapy in HPV-related small cell cancer: a case report. J Immunother Cancer. 2018 May 09; 6(1):33. PMID: 29743117.
      View in: PubMed
    11. Motz K, Herbert RJ, Fakhry C, Quon H, Kang H, Kiess AP, Eisele DW, Koch WM, Frick KD, Gourin CG. Short- and long-term outcomes of oropharyngeal cancer care in the elderly. Laryngoscope. 2018 Mar 24. PMID: 29573418.
      View in: PubMed
    12. Gourin CG, Herbert RJ, Fakhry C, Quon H, Kang H, Kiess AP, Koch WM, Eisele DW, Frick KD. Quality indicators of oropharyngeal cancer care in the elderly. Laryngoscope. 2017 Dec 15. PMID: 29243261.
      View in: PubMed
    13. Gourin CG, Fakhry C, Quon H, Kang H, Kiess AP, Herbert RJ, Eisele DW, Frick KD. Treatment, survival, and costs of oropharyngeal cancer care in the elderly. Laryngoscope. 2018 May; 128(5):1103-1112. PMID: 28988469.
      View in: PubMed
    14. Schmitt NC, Kang H, Sharma A. Salivary duct carcinoma: An aggressive salivary gland malignancy with opportunities for targeted therapy. Oral Oncol. 2017 Nov; 74:40-48. PMID: 29103750.
      View in: PubMed
    15. Guerrero-Preston R, White JR, Godoy-Vitorino F, Rodríguez-Hilario A, Navarro K, González H, Michailidi C, Jedlicka A, Canapp S, Bondy J, Dziedzic A, Mora-Lagos B, Rivera-Alvarez G, Ili-Gangas C, Brebi-Mieville P, Westra W, Koch W, Kang H, Marchionni L, Kim Y, Sidransky D. High-resolution microbiome profiling uncovers Fusobacterium nucleatum, Lactobacillus gasseri/johnsonii, and Lactobacillus vaginalis associated to oral and oropharyngeal cancer in saliva from HPV positive and HPV negative patients treated with surgery and chemo-radiation. Oncotarget. 2017 Dec 19; 8(67):110931-110948. PMID: 29340028.
      View in: PubMed
    16. Fung N, Faraji F, Kang H, Fakhry C. The role of human papillomavirus on the prognosis and treatment of oropharyngeal carcinoma. Cancer Metastasis Rev. 2017 Sep; 36(3):449-461. PMID: 28812214.
      View in: PubMed
    17. Britt CJ, Chang HY, Quon H, Kang H, Kiess AP, Eisele DW, Frick KD, Gourin CG. Quality indicators of laryngeal cancer care in commercially insured patients. Laryngoscope. 2017 12; 127(12):2805-2812. PMID: 28688188.
      View in: PubMed
    18. Day AT, Chang HY, Quon H, Kang H, Kiess AP, Eisele DW, Frick KD, Gourin CG. Treatment, short-term outcomes, and costs associated with larynx cancer care in commercially insured patients. Laryngoscope. 2018 01; 128(1):91-101. PMID: 28685830.
      View in: PubMed
    19. Dalton WB, Forde PM, Kang H, Connolly RM, Stearns V, Gocke CD, Eshleman JR, Axilbund J, Petry D, Geoghegan C, Wolff AC, Loeb DM, Pratilas CA, Meyer CF, Christenson ES, Slater SA, Ensminger J, Parsons HA, Park BH, Lauring J. Personalized Medicine in the Oncology Clinic: Implementation and Outcomes of the Johns Hopkins Molecular Tumor Board. JCO Precis Oncol. 2017; 2017. PMID: 30003184.
      View in: PubMed
    20. Ozawa H, Ranaweera RS, Izumchenko E, Makarev E, Zhavoronkov A, Fertig EJ, Howard JD, Markovic A, Bedi A, Ravi R, Perez J, Le QT, Kong CS, Jordan RC, Wang H, Kang H, Quon H, Sidransky D, Chung CH. SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells. Clin Cancer Res. 2017 Sep 01; 23(17):5162-5175. PMID: 28522603.
      View in: PubMed
    21. Bauml J, Seiwert TY, Pfister DG, Worden F, Liu SV, Gilbert J, Saba NF, Weiss J, Wirth L, Sukari A, Kang H, Gibson MK, Massarelli E, Powell S, Meister A, Shu X, Cheng JD, Haddad R. Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. J Clin Oncol. 2017 May 10; 35(14):1542-1549. PMID: 28328302.
      View in: PubMed
    22. Malm IJ, Fan CJ, Yin LX, Li DX, Koch WM, Gourin CG, Pitman KT, Richmon JD, Westra WH, Kang H, Quon H, Eisele DW, Fakhry C. Evaluation of proposed staging systems for human papillomavirus-related oropharyngeal squamous cell carcinoma. Cancer. 2017 05 15; 123(10):1768-1777. PMID: 28055120.
      View in: PubMed
    23. Anagnostou V, Smith KN, Forde PM, Niknafs N, Bhattacharya R, White J, Zhang T, Adleff V, Phallen J, Wali N, Hruban C, Guthrie VB, Rodgers K, Naidoo J, Kang H, Sharfman W, Georgiades C, Verde F, Illei P, Li QK, Gabrielson E, Brock MV, Zahnow CA, Baylin SB, Scharpf RB, Brahmer JR, Karchin R, Pardoll DM, Velculescu VE. Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. Cancer Discov. 2017 03; 7(3):264-276. PMID: 28031159.
      View in: PubMed
    24. D'Souza G, Westra WH, Wang SJ, van Zante A, Wentz A, Kluz N, Rettig E, Ryan WR, Ha PK, Kang H, Bishop J, Quon H, Kiess AP, Richmon JD, Eisele DW, Fakhry C. Differences in the Prevalence of Human Papillomavirus (HPV) in Head and Neck Squamous Cell Cancers by Sex, Race, Anatomic Tumor Site, and HPV Detection Method. JAMA Oncol. 2016 Dec 08. PMID: 27930766.
      View in: PubMed
    25. Chow LQM, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, Berger R, Eder JP, Burtness B, Lee SH, Keam B, Kang H, Muro K, Weiss J, Geva R, Lin CC, Chung HC, Meister A, Dolled-Filhart M, Pathiraja K, Cheng JD, Seiwert TY. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. J Clin Oncol. 2016 Nov 10; 34(32):3838-3845. PMID: 27646946.
      View in: PubMed
    26. Kang H, Tan M, Bishop JA, Jones S, Sausen M, Ha PK, Agrawal N. Whole-Exome Sequencing of Salivary Gland Mucoepidermoid Carcinoma. Clin Cancer Res. 2017 Jan 01; 23(1):283-288. PMID: 27340278.
      View in: PubMed
    27. Taghipour M, Sheikhbahaei S, Wray R, Agrawal N, Richmon J, Kang H, Subramaniam RM. FDG PET/CT in Patients With Head and Neck Squamous Cell Carcinoma After Primary Surgical Resection With or Without Chemoradiation Therapy. AJR Am J Roentgenol. 2016 May; 206(5):1093-100. PMID: 26999264.
      View in: PubMed
    28. Chung CH, Rudek MA, Kang H, Marur S, John P, Tsottles N, Bonerigo S, Veasey A, Kiess A, Quon H, Cmelak A, Murphy BA, Gilbert J. A phase I study afatinib/carboplatin/paclitaxel induction chemotherapy followed by standard chemoradiation in HPV-negative or high-risk HPV-positive locally advanced stage III/IVa/IVb head and neck squamous cell carcinoma. Oral Oncol. 2016 Feb; 53:54-9. PMID: 26705063.
      View in: PubMed
    29. Sheikhbahaei S, Ahn SJ, Moriarty E, Kang H, Fakhry C, Subramaniam RM. Intratherapy or Posttherapy FDG PET or FDG PET/CT for Patients With Head and Neck Cancer: A Systematic Review and Meta-analysis of Prognostic Studies. AJR Am J Roentgenol. 2015 Nov; 205(5):1102-13. PMID: 26496559.
      View in: PubMed
    30. Wang Y, Springer S, Mulvey CL, Silliman N, Schaefer J, Sausen M, James N, Rettig EM, Guo T, Pickering CR, Bishop JA, Chung CH, Califano JA, Eisele DW, Fakhry C, Gourin CG, Ha PK, Kang H, Kiess A, Koch WM, Myers JN, Quon H, Richmon JD, Sidransky D, Tufano RP, Westra WH, Bettegowda C, Diaz LA, Papadopoulos N, Kinzler KW, Vogelstein B, Agrawal N. Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas. Sci Transl Med. 2015 Jun 24; 7(293):293ra104. PMID: 26109104; PMCID: PMC4587492.
    31. Pasha MA, Marcus C, Fakhry C, Kang H, Kiess AP, Subramaniam RM. FDG PET/CT for Management and Assessing Outcomes of Squamous Cell Cancer of the Oral Cavity. AJR Am J Roentgenol. 2015 Aug; 205(2):W150-61. PMID: 26001119.
      View in: PubMed
    32. Chung CH, Guthrie VB, Masica DL, Tokheim C, Kang H, Richmon J, Agrawal N, Fakhry C, Quon H, Subramaniam RM, Zuo Z, Seiwert T, Chalmers ZR, Frampton GM, Ali SM, Yelensky R, Stephens PJ, Miller VA, Karchin R, Bishop JA. Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing. Ann Oncol. 2015 Jun; 26(6):1216-23. PMID: 25712460.
      View in: PubMed
    33. Kang H, Kiess A, Chung CH. Emerging biomarkers in head and neck cancer in the era of genomics. Nat Rev Clin Oncol. 2015 Jan; 12(1):11-26. PMID: 25403939.
      View in: PubMed
    34. Mohandas A, Marcus C, Kang H, Truong MT, Subramaniam RM. FDG PET/CT in the management of nasopharyngeal carcinoma. AJR Am J Roentgenol. 2014 Aug; 203(2):W146-57. PMID: 25055290.
      View in: PubMed
    35. Chung CH, Lee JW, Slebos RJ, Howard JD, Perez J, Kang H, Fertig EJ, Considine M, Gilbert J, Murphy BA, Nallur S, Paranjape T, Jordan RC, Garcia J, Burtness B, Forastiere AA, Weidhaas JB. A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2014 Nov; 25(11):2230-6. PMID: 25081901.
      View in: PubMed
    36. Marcus C, Ciarallo A, Tahari AK, Mena E, Koch W, Wahl RL, Kiess AP, Kang H, Subramaniam RM. Head and neck PET/CT: therapy response interpretation criteria (Hopkins Criteria)-interreader reliability, accuracy, and survival outcomes. J Nucl Med. 2014 Sep; 55(9):1411-6. PMID: 24947059.
      View in: PubMed
    37. Kang H, Gillespie TW, Goodman M, Brodie SA, Brandes M, Ribeiro M, Ramalingam SS, Shin DM, Khuri FR, Brandes JC. Long-term use of valproic acid in US veterans is associated with a reduced risk of smoking-related cases of head and neck cancer. Cancer. 2014 May 01; 120(9):1394-400. PMID: 24664792.
      View in: PubMed
    38. Brodie SA, Li G, El-Kommos A, Kang H, Ramalingam SS, Behera M, Gandhi K, Kowalski J, Sica GL, Khuri FR, Vertino PM, Brandes JC. Class I HDACs are mediators of smoke carcinogen-induced stabilization of DNMT1 and serve as promising targets for chemoprevention of lung cancer. Cancer Prev Res (Phila). 2014 Mar; 7(3):351-61. PMID: 24441677.
      View in: PubMed
    39. Alviar CL, Devarapally S, Nadkarni GN, Romero J, Benjo AM, Javed F, Doherty B, Kang H, Bangalore S, Messerli FH. Efficacy and safety of dual calcium channel blockade for the treatment of hypertension: a meta-analysis. Am J Hypertens. 2013 Feb; 26(2):287-97. PMID: 23382415.
      View in: PubMed
    40. Kim WY, Kim MJ, Moon H, Yuan P, Kim JS, Woo JK, Zhang G, Suh YA, Feng L, Behrens C, Van Pelt CS, Kang H, Lee JJ, Hong WK, Wistuba II, Lee HY. Differential impacts of insulin-like growth factor-binding protein-3 (IGFBP-3) in epithelial IGF-induced lung cancer development. Endocrinology. 2011 Jun; 152(6):2164-73. PMID: 21447628.
      View in: PubMed
    41. Kang H, Kauh JS. Chemotherapy in the treatment of metastatic gastric cancer: is there a global standard? Curr Treat Options Oncol. 2011 Mar; 12(1):96-106. PMID: 21274667.
      View in: PubMed
    42. Kang H, Rha SY, Oh KW, Nam CM. Green tea consumption and stomach cancer risk: a meta-analysis. Epidemiol Health. 2010 Apr 26; 32:e2010001. PMID: 21191454.
      View in: PubMed
    43. Kim H, Kim EK, Choi ES, Kim YJ, Lee HJ, Kim JJ, Jang HS, Shim KS, Jeon SN, Kang YH, Kang H, Oh J, Cho KS, Kwon S. [The determinants of adolescent smoking by gender and type of school in Korea]. J Prev Med Public Health. 2006 Sep; 39(5):379-88. PMID: 17076178.
      View in: PubMed
    44. Donato NJ, Perez M, Kang H, Siddik ZH, Ling YH, Perez-Soler R. EGF receptor and p21WAF1 expression are reciprocally altered as ME-180 cervical carcinoma cells progress from high to low cisplatin sensitivity. Clin Cancer Res. 2000 Jan; 6(1):193-202. PMID: 10656450.
      View in: PubMed